abstract
Breast carcinomas rarely metastasize to the ovary and are even more
rarely present clinically as primary ovarian tumors. However, patients
with breast cancer not infrequently develop independent primary ovarian
carcinomas. In these cases, distinction between independent primaries
and metastatic tumors is crucial. Several comparative
immunohistochemical studies have been reported, but few included
significant clinicopathologic data and none investigated cases of
ovarian and breast carcinomas from the same patients. In this study, we
compared 18 cases of patients with bona fide independent breast and
ovarian carcinomas (15 high-grade serous and 3 clear cell carcinomas),
with 9 cases of patients with known mammary carcinomas (7 lobular and 2
ductal carcinomas) metastatic to the ovary. Immunohistochemical stains
for Pax-8, WT-1, and GATA3 were carried out on tissue microarrays (TMA).
Most primary ovarian carcinomas were larger than the metastatic tumors (P=0.001)
and were diagnosed at an advanced stage. All primary ovarian tumors
showed marked nuclear pleomorphism, whereas only 2 metastatic breast
carcinomas had Grade 3 nuclei (P=0.000). The vast majority of
ovarian metastases (7/9) showed the typical pattern of lobular breast
carcinoma. Pax-8 and WT-1 expression were found in 16 of 18 (88%) and 13
of 18 (72%) primary ovarian carcinomas, respectively. In contrast, all
primary ovarian carcinomas were negative for GATA3. The 2 Pax-8-negative
ovarian carcinomas were also negative for WT-1. With the exception of 3
triple-negative carcinomas, all primary breast carcinomas were positive
for GATA3. All metastatic breast carcinomas were positive for GATA3 and
negative for Pax-8. WT-1 expression was seen in only 1 of 9 metastatic
breast carcinomas (11%). Patients with ovarian metastases had worse
prognosis than patients with independent breast and ovarian carcinomas (P=0.000).
Pax-8, WT-1, and GATA3 immunoreactions are useful in the distinction
between independent primaries and metastatic mammary carcinomas to the
ovary in the light of clinicopathologic findings.
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.